Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma
2018/09/05 by Damian Stichel, Azadeh Ebrahimi, David Reuß +16 · 28 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Glioma Diagnosis and Treatment #Chromatin Remodeling and Cancer #MicroRNA in disease regulation
paper · doi:10.1007/s00401-018-1905-0
Cited by
- +7/−10 chromosome copy-number alteration in the elderly: A cautionary tale from 2 cases
- Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas
- Comparison of Fluorescence In Situ Hybridization, Next-Generation Sequencing, and DNA Methylation Microarray for Copy Number Variation Assessment in Gliomas
- cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". [europepmc]
- Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. [europepmc]
- Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. [europepmc]
- Total copy number variation as a prognostic factor in adult astrocytoma subtypes. [europepmc]
- Cryptotanshinone Suppresses Non-Small Cell Lung Cancer via microRNA-146a-5p/EGFR Axis. [europepmc]
- Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. [europepmc]
- Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. [europepmc]
- Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. [europepmc]
- Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target. [europepmc]
- Chromosome Abnormalities: New Insights into Their Clinical Significance in Cancer. [europepmc]
- Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas. [europepmc]
- Clinical Management of Diffuse Low-Grade Gliomas. [europepmc]
- Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. [europepmc]
- MRI Features May Predict Molecular Features of Glioblastoma in Isocitrate Dehydrogenase Wild-Type Lower-Grade Gliomas. [europepmc]
- Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. [europepmc]
- Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma. [europepmc]
- Prognostic and Predictive Biomarkers in Gliomas. [europepmc]
- Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. [europepmc]
- Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. [europepmc]
- Molecular and Circulating Biomarkers in Patients with Glioblastoma. [europepmc]
- Adult type diffuse gliomas in the new 2021 WHO Classification. [europepmc]
- Single-cell RNA sequencing and spatial transcriptomics reveal cancer-associated fibroblasts in glioblastoma with protumoral effects. [europepmc]
- Glioblastoma Therapy: Past, Present and Future. [europepmc]
- Principles in the Management of Glioblastoma. [europepmc]
- Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches. [europepmc]